title: Calcium channel blockers reduce oxaliplatin-induced acute neuropathy: a retrospective study of 69 male patients receiving modified FOLFOX6 therapy.
abstract: Oxaliplatin-based chemotherapy has been widely used for colorectal cancer. However, it causes severe acute and chronic peripheral neuropathies. Recently, we reported that calcium channel blockers prevent the oxaliplatin-induced cold hyperalgesia in rats. The purpose of this study was to determine whether the treatment with calcium channel blockers prevents the peripheral neuropathy during oxaliplatin therapy. The electronic medical charts for patients who received modified FOLFOX6 regimen from January 2008 to December 2010 were evaluated. Of the 200 patients who received modified FOLFOX6 therapy, 84 patients were excluded due to the exclusion criteria. Calcium channel blockers had been taken by 26 of 69 male patients, but only three of 47 female patients. Therefore, in the present analysis, the male data of the groups with and without calcium channel blockers (n=26 and 43, respectively) were compared. The cumulative incidence curve of acute neuropathy was significantly lower in the group with calcium channel blockers (P=0.0438, log-rank test), whereas there was no difference between these groups in the cumulative incidence curve of chronic neuropathy (P=0.4919, log-rank test). The present study indicated that calcium channel blockers inhibit the development of acute peripheral neuropathy in patients receiving modified FOLFOX6 therapy.
authors.affiliation: Department of Pharmacy, Kyushu University Hospital, Maidashi, Higashi-ku, Fukuoka, Japan.
authors.forename: Yoko
authors.initials: Y
authors.lastname: Tatsushima
authors.forename: Nobuaki
authors.initials: N
authors.lastname: Egashira
authors.forename: Yuri
authors.initials: Y
authors.lastname: Narishige
authors.forename: Shiori
authors.initials: S
authors.lastname: Fukui
authors.forename: Takehiro
authors.initials: T
authors.lastname: Kawashiri
authors.forename: Yui
authors.initials: Y
authors.lastname: Yamauchi
authors.forename: Ryozo
authors.initials: R
authors.lastname: Oishi
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D002955:Leucovorin / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000077150:Oxaliplatin; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced / Q000517:prevention & control*; D012189:Retrospective Studies
chemical_list: D002121:Calcium Channel Blockers; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D002955:Leucovorin; D005472:Fluorouracil